Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Mar 18, 2024 3:37pm
110 Views
Post# 35938972

RE:RepliCel Life signs LOI with CEO for asset purchase

RE:RepliCel Life signs LOI with CEO for asset purchaseInteresiting.  Not sure  how this  works  if the shares are delisted.

Following this  shareholders  get  between  3%  and 8%  of  any  profits  from  sale  of  the  four assets.

Likely  2 to 3 years  out  from  now!   Also  there is the word  profit?  If the assets are  given away,  is  ant  purchase  revenue  profit  or  is  marketing cost deducted from that.  Basically  Andrew will try to sell  what is left  and  take 92%  of whatever he can get???

Wonder what the value of the company as a shell with   new  venture vended in  would  be.?

Why  not  sell th assets  , have new people  use the shell and have current shareholders  get  their  percentage   -  ie  2  paths.  Now  basically  just a hope that something can be salvaged,   Hope that  there is not an asset sale to sheiseido??  

GLTA

VGLTA!!!
<< Previous
Bullboard Posts
Next >>